SARS-CoV-2 3C-like protease antagonizes interferon-beta production by facilitating the degradation of IRF3
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 3C-like protease antagonizes interferon-beta production by facilitating the degradation of IRF3
Authors
Keywords
SARS-CoV-2 3CL, RLR signalling pathway, IFNs, Innate immune, IRF3
Journal
CYTOKINE
Volume 148, Issue -, Pages 155697
Publisher
Elsevier BV
Online
2021-09-03
DOI
10.1016/j.cyto.2021.155697
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overview of antiviral drug candidates targeting coronaviral 3C‐like main proteases
- (2021) Chun‐Chi Chen et al. FEBS Journal
- Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19
- (2021) Molly K. Roe et al. JOURNAL OF GENERAL VIROLOGY
- Diagnosis of COVID-19, vitality of emerging technologies and preventive measures
- (2021) Muhammad Asif et al. CHEMICAL ENGINEERING JOURNAL
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
- (2020) Victor M Corman et al. Eurosurveillance
- BICP0 Negatively Regulates TRAF6-Mediated NF-κB and Interferon Activation by Promoting K48-Linked Polyubiquitination of TRAF6
- (2020) Chong Cao et al. Frontiers in Microbiology
- Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
- (2020) Jasper Fuk-Woo Chan et al. Emerging Microbes & Infections
- Author Correction: A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
- (2020) Jean-Michel Sallenave et al. Frontiers in Immunology
- Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
- (2020) Muhammad Tahir ul Qamar et al. Journal of Pharmaceutical Analysis
- Coronavirus Disease 2019–COVID-19
- (2020) Kuldeep Dhama et al. CLINICAL MICROBIOLOGY REVIEWS
- Activation and evasion of type I interferon responses by SARS-CoV-2
- (2020) Xiaobo Lei et al. Nature Communications
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
- (2020) Ahmad Abu Turab Naqvi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors
- (2020) Alina S. Shomuradova et al. IMMUNITY
- Forkhead box O1-mediated ubiquitination suppresses RIG-I-mediated antiviral immune responses
- (2020) Zhenling Ma et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Dual targeting of RIG-I and MAVS by MARCH5 mitochondria ubiquitin ligase in innate immunity
- (2019) Yeon-Ji Park et al. CELLULAR SIGNALLING
- Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses
- (2017) Wei Liu et al. eLife
- Methylcrotonoyl-CoA carboxylase 1 potentiates RLR-induced NF-κB signaling by targeting MAVS complex
- (2016) Zhongying Cao et al. Scientific Reports
- Codon optimization enhances the expression of porcine β-defensin-2 in Escherichia coli
- (2015) C.Y. Gao et al. GENETICS AND MOLECULAR RESEARCH
- MAVS Coordination of Antiviral Innate Immunity
- (2015) Christine Vazquez et al. JOURNAL OF VIROLOGY
- Dynamic control of type I IFN signalling by an integrated network of negative regulators
- (2015) Rebecca A. Porritt et al. TRENDS IN IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started